GZMM抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: RAW264.7 cell, Primary antibody: P05779(GZMM Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P05779(GZMM Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The GZMM antibody targets Granzyme M (GZMM), a serine protease in the granzyme family, primarily expressed by natural killer (NK) cells and cytotoxic T lymphocytes. GZMM is stored in cytotoxic granules and released upon immune cell activation to induce apoptosis in infected or malignant cells. Unlike the well-characterized Granzyme B, which activates caspase-dependent apoptosis, GZMM triggers cell death through caspase-independent pathways, such as cleaving nuclear or mitochondrial proteins, and may contribute to inflammation regulation.

GZMM antibodies are critical tools for studying its expression, localization, and function in immune responses. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to explore GZMM’s role in infections, cancer immunosurveillance, and autoimmune disorders. Research suggests GZMM may influence tumor progression, viral clearance, and inflammatory diseases, but its mechanisms remain less understood compared to other granzymes.

These antibodies also aid in developing therapeutic strategies, such as enhancing cytotoxic activity in immunotherapy or modulating excessive inflammation. Challenges include ensuring antibody specificity due to structural similarities among granzymes. Overall, GZMM antibodies provide insights into immune cell biology and potential clinical applications, bridging gaps in understanding cytotoxic lymphocyte functions.